Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 1.00 |
| ▸ | EGFR | P00533 | 17/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 16/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837022 | 0.87 | KDR (1.00) | KDREGFRPDGFRBPDGFRA | |
| SCHEMBL17858425 | 0.86 | KDR (1.00) | KDREGFRPDGFRBPDGFRA | |
| SCHEMBL17837008 | 0.86 | KDR (1.00) | KDREGFRPDGFRBPDGFRA | |
| SCHEMBL17837015 | 0.84 | KDR (0.82) | KDREGFRPDGFRBPDGFRA | |
| SCHEMBL17837030 | 0.84 | KDR (1.00) | KDREGFRPDGFRBPDGFRA | |
| SCHEMBL22432432 | 0.83 | KDR (0.71) | KDREGFRPDGFRBPDGFRA | |
| SCHEMBL17837012 | 0.83 | PDGFRB (1.00) | KDREGFRPDGFRBPDGFRA | |
| SCHEMBL13276054 | 0.81 | KDR (0.68) | KDREGFRPDGFRBPDGFRA | |
| SCHEMBL4845879 | 0.77 | KDR (0.62) | KDREGFRPDGFRBPDGFRA | |
| SCHEMBL18552090 | 0.76 | KDR (0.71) | KDREGFRPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459927-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4210694-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12331119-B2 | Modified Fc fragment, antibody comprising same, and application thereof | WUHAN YZY BIOPHARMA CO., LTD. (CN) | 2025-06-17 | — | — | US | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-115989224-B | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119331967-A | Kit and application thereof | 南京梅里医药科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-4359381-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117858707-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| US-8946239-B2 | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946239-B2 | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946239-B2 | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140303188-A1 | Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antitmitotic And/Or Antitumor Activity And Methods Of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303188-A1 | Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antitmitotic And/Or Antitumor Activity And Methods Of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303188-A1 | Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antitmitotic And/Or Antitumor Activity And Methods Of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2014-10-09 | — | — | US | disclosed |
| US-20100010016-A1 | BICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2010-01-14 | — | — | US | disclosed |
| WO-2010006025-A1 | BICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20100010016-A1 | BICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2010-01-14 | — | — | US | disclosed |
| US-20100010016-A1 | BICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | KDR 2352/4885EGFR 1637/4885PDGFRB 1728/4885 |
| US-20100010016-A1 | BICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCC1, ABCB1, ABCG2 | KDR 4053/4885EGFR 3337/4885PDGFRB 4490/4885 |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | KDR 1430/4885EGFR 571/4885PDGFRB 574/4885 |
| US-12325697-B2 | CBL-B modulators and uses thereof | CBLB, CBL, CBLC | KDR 1430/4885EGFR 571/4885PDGFRB 574/4885 |
| US-12459927-B2 | Plasma kallikrein inhibitors | KLKB1, SERPINE1, KLK5 | KDR 75/4885EGFR 2640/4885PDGFRB 2212/4885 |
| US-20140303188-A1 | Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antitmitotic And/Or Antitumor Activity And Methods Of Use Thereof | ABCC1, ABCG2, ABCB1 | KDR 4359/4885EGFR 2592/4885PDGFRB 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.